IL1B and leukemia: Although PON demonstrated good results for treating patients with leukemia, it also exhibited severe side effects, including cardiotoxicity; a recent study reported that it caused myocardial and systemic inflammation due to the activation of the S100A8/A9-TLR4-NLPR3-IL-1β signaling pathway [83].